Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, Texas, United States of America.
PLoS One. 2019 Feb 22;14(2):e0208216. doi: 10.1371/journal.pone.0208216. eCollection 2019.
Pneumonia remains a global health threat, in part due to expanding categories of susceptible individuals and increasing prevalence of antibiotic resistant pathogens. However, therapeutic stimulation of the lungs' mucosal defenses by inhaled exposure to a synergistic combination of Toll-like receptor (TLR) agonists known as Pam2-ODN promotes mouse survival of pneumonia caused by a wide array of pathogens. This inducible resistance to pneumonia relies on intact lung epithelial TLR signaling, and inducible protection against viral pathogens has recently been shown to require increased production of epithelial reactive oxygen species (ROS) from multiple epithelial ROS generators. To determine whether similar mechanisms contribute to inducible antibacterial responses, the current work investigates the role of ROS in therapeutically-stimulated protection against Pseudomonas aerugnosa challenges. Inhaled Pam2-ODN treatment one day before infection prevented hemorrhagic lung cytotoxicity and mouse death in a manner that correlated with reduction in bacterial burden. The bacterial killing effect of Pam2-ODN was recapitulated in isolated mouse and human lung epithelial cells, and the protection correlated with inducible epithelial generation of ROS. Scavenging or targeted blockade of ROS production from either dual oxidase or mitochondrial sources resulted in near complete loss of Pam2-ODN-induced bacterial killing, whereas deficiency of induced antimicrobial peptides had little effect. These findings support a central role for multisource epithelial ROS in inducible resistance against a bacterial pathogen and provide mechanistic insights into means to protect vulnerable patients against lethal infections.
肺炎仍然是一个全球性的健康威胁,部分原因是易感人群的类别不断扩大,以及对抗生素耐药病原体的流行率不断增加。然而,通过吸入已知为 Pam2-ODN 的 Toll 样受体 (TLR) 激动剂的协同组合来治疗性地刺激肺部黏膜防御,可促进对多种病原体引起的肺炎的小鼠存活。这种对肺炎的诱导性抵抗力依赖于完整的肺上皮 TLR 信号,最近已经表明,针对病毒病原体的诱导性保护需要来自多个上皮 ROS 生成器的上皮反应性氧物种 (ROS) 的增加产生。为了确定类似的机制是否有助于诱导性抗细菌反应,目前的工作研究了 ROS 在治疗性刺激对铜绿假单胞菌挑战的保护中的作用。在感染前一天吸入 Pam2-ODN 治疗可防止出血性肺细胞毒性和小鼠死亡,其方式与细菌负荷减少相关。Pam2-ODN 的杀菌作用在分离的小鼠和人肺上皮细胞中得到重现,并且与诱导性上皮 ROS 的产生相关。从双氧化酶或线粒体来源清除或靶向阻断 ROS 的产生会导致 Pam2-ODN 诱导的细菌杀伤几乎完全丧失,而诱导性抗微生物肽的缺乏几乎没有影响。这些发现支持上皮多源 ROS 在针对细菌病原体的诱导性抵抗力中的核心作用,并为保护易受感染的患者免受致死性感染提供了机制上的见解。